NASDAQ:CRSP - CRISPR Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $158.80
  • Forecasted Upside: 38.51 %
  • Number of Analysts: 18
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$114.65
▼ -0.84 (-0.73%)
1 month | 3 months | 12 months
Get New CRISPR Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRSP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRSP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$158.80
▲ +38.51% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for CRISPR Therapeutics in the last 3 months. The average price target is $158.80, with a high forecast of $210.00 and a low forecast of $110.00. The average price target represents a 38.51% upside from the last price of $114.65.
Buy
The current consensus among 18 investment analysts is to buy stock in CRISPR Therapeutics. This rating has held steady since September 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 2 sell ratings
9/13/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 1 sell ratings
12/12/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 1 sell ratings
3/11/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 1 sell ratings
6/9/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/7/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 2 sell ratings
12/6/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 2 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 2 sell ratings
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2021JMP SecuritiesInitiated CoverageOutperform$160.00High
i
3/1/2021BarclaysBoost Price TargetOverweight$113.00 ➝ $140.00Low
i
2/28/2021BarclaysReiterated RatingBuyLow
i
2/17/2021The Goldman Sachs GroupLower Price TargetNeutral$193.00 ➝ $189.00Medium
i
2/17/2021OppenheimerBoost Price TargetOutperform$165.00 ➝ $187.00Low
i
2/17/2021Chardan CapitalBoost Price TargetBuy$166.00 ➝ $175.00Low
i
2/17/2021Needham & Company LLCReiterated RatingBuyLow
i
1/12/2021TruistBoost Price Target$170.00 ➝ $210.00Low
i
12/10/2020Chardan CapitalBoost Price TargetBuy$110.00 ➝ $166.00High
i
Rating by Geulah Livshits at Chardan Capital
12/10/2020Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
i
12/10/2020Needham & Company LLCBoost Price TargetBuy$105.00 ➝ $170.00Medium
i
Rating by Alan Carr at Needham & Company LLC
12/10/2020Piper SandlerBoost Price TargetOverweight$107.00 ➝ $180.00Medium
i
Rating by Edward Tenthoff at Piper Sandler
12/7/2020Stifel NicolausBoost Price TargetHold ➝ Positive$91.00 ➝ $145.00High
i
12/7/2020Canaccord GenuityBoost Price TargetBuy$120.00 ➝ $151.00Low
i
12/7/2020OppenheimerBoost Price TargetOutperform$105.00 ➝ $155.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/7/2020Roth CapitalBoost Price TargetBuy$115.00 ➝ $170.00High
i
12/7/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$102.63 ➝ $145.00Low
i
10/30/2020Raymond JamesReiterated RatingSellHigh
i
10/29/2020Piper SandlerLower Price TargetOverweight$128.00 ➝ $107.00Medium
i
Rating by Edward Tenthoff at Piper Sandler
10/22/2020Royal Bank of CanadaInitiated CoverageSector Perform$110.00 ➝ $110.00Medium
i
10/22/2020Canaccord GenuityBoost Price Target$110.00 ➝ $120.00High
i
10/22/2020Chardan CapitalBoost Price TargetPositive ➝ Buy$100.00 ➝ $110.00High
i
Rating by Geulah Livshits at Chardan Capital
10/21/2020Stifel NicolausBoost Price TargetHold$75.00 ➝ $93.00Medium
i
10/21/2020Roth CapitalBoost Price TargetBuy$105.00 ➝ $115.00High
i
10/21/2020Piper SandlerBoost Price TargetOverweight$104.00 ➝ $128.00High
i
Rating by Edward Tenthoff at Piper Sandler
10/5/2020Bank of AmericaInitiated CoverageBuy$110.00 ➝ $110.00High
i
8/5/2020CitigroupReiterated RatingSellLow
i
7/28/2020Wells Fargo & CompanyBoost Price TargetOverweight$95.00 ➝ $110.00High
i
7/28/2020Chardan CapitalBoost Price TargetBuy$72.50 ➝ $100.00High
i
Rating by Geulah Livshits at Chardan Capital
7/28/2020Needham & Company LLCBoost Price TargetBuy$84.00 ➝ $105.00Medium
i
Rating by Alan Carr at Needham & Company LLC
7/28/2020William BlairReiterated RatingBuyMedium
i
7/28/2020BarclaysBoost Price TargetPositive ➝ Overweight$65.00 ➝ $102.00High
i
7/27/2020OppenheimerInitiated CoverageBuy$89.00 ➝ $105.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/14/2020SunTrust BanksInitiated CoverageBuy$140.00Low
i
6/23/2020OppenheimerBoost Price TargetOutperform$80.00 ➝ $89.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
6/19/2020Piper SandlerReiterated RatingOverweight$104.00High
i
Rating by Edward Tenthoff at Piper Sandler
6/19/2020Roth CapitalBoost Price TargetBuy$100.00 ➝ $105.00Medium
i
6/15/2020Canaccord GenuityBoost Price TargetBuy$80.00 ➝ $84.00High
i
6/12/2020Piper SandlerReiterated RatingBuy$104.00Medium
i
Rating by Edward Tenthoff at Piper Sandler
6/12/2020Chardan CapitalReiterated RatingBuy$72.50Medium
i
Rating by Geulah Livshits at Chardan Capital
6/12/2020Needham & Company LLCInitiated CoverageBuy$84.00Medium
i
Rating by Alan Carr at Needham & Company LLC
6/12/2020OppenheimerInitiated CoverageBuy$80.00Low
i
5/31/2020Chardan CapitalReiterated RatingBuyMedium
i
Rating by Geulah Livshits at Chardan Capital
5/6/2020Chardan CapitalReiterated RatingBuyMedium
i
Rating by Geulah Livshits at Chardan Capital
4/29/2020Needham & Company LLCInitiated CoverageBuy$84.00High
i
Rating by Alan Carr at Needham & Company LLC
4/28/2020William BlairReiterated RatingBuyHigh
i
Rating by R. Prasad at William Blair
4/1/2020Piper SandlerReiterated RatingBuy$104.00Low
i
Rating by Edward Tenthoff at Piper Sandler
3/4/2020Stifel NicolausInitiated CoverageHold$52.00Low
i
3/4/2020CitigroupBoost Price TargetSell$28.00 ➝ $31.00Medium
i
2/13/2020Piper SandlerReiterated RatingBuy$104.00High
i
Rating by Edward Tenthoff at Piper Sandler
2/13/2020Chardan CapitalReiterated RatingBuy$72.50High
i
Rating by Geulah Livshits at Chardan Capital
2/13/2020William BlairReiterated RatingBuyHigh
i
Rating by R. Prasad at William Blair
1/30/2020Chardan CapitalReiterated RatingBuyMedium
i
Rating by Geulah Livshits at Chardan Capital
12/23/2019Needham & Company LLCReiterated RatingBuy$84.00High
i
12/16/2019Piper Jaffray CompaniesReiterated RatingBuy$104.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
12/6/2019Wells Fargo & CompanyReiterated RatingBuyLow
i
11/26/2019Piper Jaffray CompaniesReiterated RatingBuy$104.00Medium
i
Rating by Edward Tenthoff at Piper Jaffray Companies
11/25/2019OppenheimerBoost Price TargetOutperform$65.00 ➝ $80.00Low
i
11/20/2019Canaccord GenuityBoost Price TargetBuy ➝ Positive$72.00 ➝ $80.00High
i
Rating by Arlinda Lee at Canaccord Genuity
11/19/2019Roth CapitalBoost Price Target$65.00 ➝ $100.00High
i
Rating by T. Butler at Roth Capital
11/19/2019Piper Jaffray CompaniesBoost Price TargetBuy$100.00 ➝ $107.00High
i
11/19/2019Wells Fargo & CompanyReiterated RatingBuyHigh
i
11/19/2019William BlairUpgradeMarket Perform ➝ OutperformHigh
i
Rating by R. Prasad at William Blair
11/19/2019The Goldman Sachs GroupBoost Price TargetPositive ➝ Neutral$52.00 ➝ $75.00High
i
11/18/2019Chardan CapitalReiterated RatingBuy$72.50High
i
Rating by Geulah Livshits at Chardan Capital
11/12/2019OppenheimerUpgradeMarket Perform ➝ Outperform$65.00High
i
10/21/2019Chardan CapitalSet Price TargetBuy$72.50Low
i
Rating by Geulah Livshits at Chardan Capital
10/21/2019Piper Jaffray CompaniesReiterated RatingOverweightHigh
i
10/15/2019Chardan CapitalReiterated RatingBuy$72.50Low
i
Rating by Geulah Livshits at Chardan Capital
8/1/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$64.00Low
i
7/31/2019Needham & Company LLCReiterated RatingBuy$62.00Low
i
7/30/2019Roth CapitalBoost Price Target$50.00 ➝ $65.00Medium
i
Rating by T. Butler at Roth Capital
7/30/2019BarclaysBoost Price TargetOverweight$59.00 ➝ $62.00Medium
i
7/30/2019BTIG ResearchBoost Price TargetBuy ➝ Positive$51.00 ➝ $59.00Medium
i
7/30/2019William BlairReiterated RatingHoldMedium
i
Rating by R. Prasad at William Blair
7/26/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$72.00High
i
6/10/2019Roth CapitalInitiated CoverageBuy$50.00Medium
i
Rating by T. Butler at Roth Capital
6/7/2019Chardan CapitalSet Price TargetBuy$73.00High
i
Rating by Geulah Livshits at Chardan Capital
5/1/2019Needham & Company LLCReiterated RatingBuy$62.00Medium
i
Rating by Alan Carr at Needham & Company LLC
4/22/2019BTIG ResearchBoost Price TargetBuy$30.00 ➝ $33.00Medium
i
4/11/2019Evercore ISIInitiated CoverageOutperformLow
i
3/13/2019William BlairInitiated CoverageMarket PerformLow
i
Rating by R. Prasad at William Blair
2/7/2019BTIG ResearchInitiated CoverageBuy$43.00Medium
i
1/28/2019The Goldman Sachs GroupDowngradeBuy ➝ Neutral$78.00 ➝ $40.00Low
i
1/22/2019CitigroupDowngradeNeutral ➝ Sell$28.00 ➝ $21.00High
i
12/31/2018SunTrust BanksReiterated RatingBuyMedium
i
12/9/2018Needham & Company LLCInitiated CoverageBuy$62.00 ➝ $38.72Low
i
Rating by Alan Carr at Needham & Company LLC
11/30/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$62.00Medium
i
10/10/2018Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$65.00High
i
10/9/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
i
Rating by Whitney Ijem at Guggenheim
9/20/2018Raymond JamesInitiated CoverageUnderperform ➝ UnderperformHigh
i
8/24/2018CitigroupLower Price TargetNeutral ➝ Neutral$51.00 ➝ $50.00Low
i
8/8/2018Chardan CapitalReiterated RatingBuy$72.50High
i
5/15/2018Chardan CapitalBoost Price TargetBuy$25.00 ➝ $72.50Medium
i
4/6/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$86.00High
i
3/9/2018SunTrust BanksReiterated RatingBuy$65.00High
i
3/9/2018Piper Jaffray CompaniesReiterated RatingOverweight$67.00 ➝ $53.70High
i
3/8/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$69.00High
i
3/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$29.00 ➝ $59.00Low
i
2/28/2018CitigroupBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $51.00Medium
i
1/23/2018SunTrust BanksUpgradeHold ➝ BuyHigh
i
1/10/2018Piper Jaffray CompaniesReiterated RatingBuy$39.00 ➝ $22.75Low
i
12/22/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ OverweightHigh
i
12/21/2017OppenheimerReiterated RatingHoldHigh
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/7/2017OppenheimerInitiated CoverageHoldLow
i
11/10/2017SunTrust BanksReiterated RatingHold$16.00N/A
i
9/8/2017BarclaysReiterated RatingBuy$29.00Low
i
8/14/2017Chardan CapitalReiterated RatingBuyMedium
i
Rating by Madhu Kumar at Chardan Capital
7/18/2017OppenheimerMarket PerformN/A
i
7/13/2017SunTrust BanksInitiated CoverageHold ➝ Hold$16.00Low
i
3/27/2017Chardan CapitalInitiated CoverageBuy ➝ Buy$23.50High
i
2/16/2017Piper Jaffray CompaniesSet Price TargetBuy$21.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
11/15/2016CitigroupInitiated CoverageNeutral$19.00N/A
i
11/14/2016GuggenheimInitiated CoverageBuy$30.00N/A
i
11/14/2016Piper Jaffray CompaniesInitiated CoverageOverweight$21.00N/A
i
11/14/2016BarclaysInitiated CoverageOverweight$22.00N/A
i
(Data available from 3/7/2016 forward)
CRISPR Therapeutics logo
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Read More

Today's Range

Now: $114.65
$100.00
$116.06

50 Day Range

MA: $162.11
$115.49
$210.04

52 Week Range

Now: $114.65
$32.30
$220.20

Volume

5,228,860 shs

Average Volume

2,551,838 shs

Market Capitalization

$8.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.37

Frequently Asked Questions

What sell-side analysts currently cover shares of CRISPR Therapeutics?

The following Wall Street research analysts have issued research reports on CRISPR Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, Canaccord Genuity, Chardan Capital, Citigroup Inc., Jefferies Financial Group Inc., JMP Securities, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Roth Capital, Royal Bank of Canada, Stifel Nicolaus, SunTrust Banks, Inc., The Goldman Sachs Group, Inc., Truist, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for CRSP.

What is the current price target for CRISPR Therapeutics?

15 Wall Street analysts have set twelve-month price targets for CRISPR Therapeutics in the last year. Their average twelve-month price target is $158.80, suggesting a possible upside of 38.5%. Truist has the highest price target set, predicting CRSP will reach $210.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $110.00 for CRISPR Therapeutics in the next year.
View the latest price targets for CRSP.

What is the current consensus analyst rating for CRISPR Therapeutics?

CRISPR Therapeutics currently has 2 sell ratings, 4 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRSP will outperform the market and that investors should add to their positions of CRISPR Therapeutics.
View the latest ratings for CRSP.

What other companies compete with CRISPR Therapeutics?

How do I contact CRISPR Therapeutics' investor relations team?

CRISPR Therapeutics' physical mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company's listed phone number is 41-41-561-3277 and its investor relations email address is [email protected] The official website for CRISPR Therapeutics is www.crisprtx.com.